我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
25
12 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
1247
进行中(未招募)
11
44.0%
已完成
9
36.0%
Enrolling By Invitation
1
4.0%
Unknown
4
16.0%
暂无批准数据
- The landmark STAR trial, the largest multicenter RCT of trauma-focused therapy for co-occurring psychosis and PTSD, enrolled 305 participants across five UK sites and found the integrated intervention both safe and highly effective. - Half of participants receiving trauma-focused CBT for psychosis (CBTp) no longer met PTSD criteria post-therapy, compared to just over 20% in the treatment-as-usual arm, with a 6.5% therapy disengagement rate. - Significant improvements were observed across 22 of 27 assessed outcomes, including PTSD severity, paranoia, hallucinations, depression, anxiety, and suicidal ideation. - The findings directly challenge the longstanding practice of excluding psychosis patients from trauma-focused therapy trials, an exclusion that researchers now call indefensible as a safety rationale.